New Insight of Cell Mechanisms and Therapeutic Approaches in Rheumatic Diseases

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Medical Biology".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 4245

Special Issue Editors


E-Mail Website
Guest Editor
Unit of Endocrinology, Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Piazza Lauro de Bosis, 006-00135 Rome, Italy
Interests: cellular biology; cell metabolism; skeletal muscle; hormones; gender medicine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Unit of Biology and Genetics of Movement, Department of Movement, Human and Health Sciences, University of Rome Foro Italico, Piazza Lauro de Bosis 6, 00135 Rome, Italy
Interests: redox homeostasis; antioxidant systems; redox signaling; oxidative stress response proteins; skeletal/cardiac muscle; muscle adaptation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Rheumatic diseases refer to a group of autoimmune and inflammatory disorders affecting joints, bones, cartilage, tendons, ligaments and muscles. These disorders affect an important fraction of the population and lead to increased health medical costs, disability and early mortality. The etiologies are complex and generally not fully understood, making the study of pathogenic mechanisms and the pharmacological approaches in these diseases a great challenge for researchers. Better characterization and understanding of the cellular and molecular events driving these disorders is critical in order to prevent the established diseases or inhibit their development, growth and worsening.

The aim of this issue “New insight of cell mechanism and therapeutic approaches in rheumatic diseases” is highlight promising researches focusing the pathogenesis, management and prevention of rheumatic diseases, including but not limited to vasculopathies, scleroderma, osteoporosis, polymyalgia rheumatica (PMR), as well as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We welcome different types of manuscript submissions, such as original articles, narrative reviews, systematic reviews, as well as meta-analyses concerning any aspect of cellular and molecular mechanism, diagnosis and treatment regarding the main rheumatic disorders, to provide a state-of-the-art overview of this issue.

Dr. Cristina Antinozzi
Prof. Dr. Ivan Dimauro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmune diseases
  • rheumatic diseases
  • pharmacological approaches
  • cell metabolism
  • molecular mechanisms
  • inflammation
  • physical therapies
  • biomarkers
  • disease prevention
  • antibodies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

35 pages, 861 KiB  
Systematic Review
The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
by Mohammad Amin Habibi, Samira Alesaeidi, Mohadeseh Zahedi, Samin Hakimi Rahmani, Seyed Mohammad Piri and Soheil Tavakolpour
Biology 2022, 11(12), 1767; https://doi.org/10.3390/biology11121767 - 6 Dec 2022
Cited by 12 | Viewed by 3415
Abstract
Background and aim: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease developed by autoantibody production against human neutrophilic granulocytes, including proteinase-3 (PR3) and myeloperoxidase (MPO). The management of AAV patients is difficult due to the multiorgan involvement, high [...] Read more.
Background and aim: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease developed by autoantibody production against human neutrophilic granulocytes, including proteinase-3 (PR3) and myeloperoxidase (MPO). The management of AAV patients is difficult due to the multiorgan involvement, high rate of relapse, and complications of immunosuppressive agents that make it challenging. This study aims to investigate the efficacy and safety of rituximab (RTX) therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) subtypes. Method: The PubMed/Medline database was searched for any studies related to RTX therapy in ANCA-associated vasculitis (GPA and MPA subtypes), from inception to 1 August 2022, and proceeded in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Our search resulted in 1082 initial records. After the elimination of review papers, irrelevant studies, and non-English records, 223 articles were included, and the data related to the efficacy and safety of RTX therapy were extracted. Several randomized and non-randomized studies showed that RTX is an effective treatment option for patients with AAV. Most of the studies showed the very effective effect of RTX in controlling disease in AAV patients, including pediatrics, adults, and elderlies, although RTX cannot completely prevent relapse. However, maintenance therapy helps delay the disease’s relapse and causes sustained remission. Not only the licensed dose (375 mg/m2 intravenous per week for 4 weeks) could induce disease remission, but studies also showed that a single infusion of RTX could be effective. Although RTX could resolve many rare manifestations in AAV patients, there are few reports showing treatment failure. Additionally, few sudies have reported the unexpeted worsening of the disease after RTX administration. Generally, RTX is relatively safe compared to conventional therapies, but some serious adverse effects, mainly infections, cytopenia, hypogammaglobinemia, malignancy, and hypersensitivity have been reported. Conclusions: RTX is an effective and relatively safe therapeutic option for AAV. Studies on the evaluation of the safety profiles of RTX and the prevention of severe RTX-related side effects in AAV patients are required. Full article
Show Figures

Figure 1

Back to TopTop